
November 7, 2017 - By Stephen Andrade
Among 15 analysts covering GlaxoSmithKline (NYSE:GSK), 6 have Buy rating, 1 Sell and 8 Hold. Therefore 40% are positive. GlaxoSmithKline had 23 analyst reports since September 8, 2015 according to SRatingsIntel. The firm has “Neutral” rating by J P Morgan Chase Co given on Friday, June 16. The firm has “Buy” rating given on Wednesday, January 27 by Bryan Garnier & Cie. The company was maintained on Wednesday, April 26 by JP Morgan. The rating was upgraded by Bank of America on Tuesday, September 8 to “Neutral”. The rating was downgraded by Morgan Stanley to “Underweight” on Friday, September 8. Argus Research maintained GlaxoSmithKline plc (ADR) (NYSE:GSK) rating on Friday, August 12. Argus Research has “Buy” rating and $50 target. The stock has “Hold” rating by Cantor Fitzgerald on Friday, February 26. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has “Neutral” rating given on Tuesday, October 20 by Credit Suisse. As per Thursday, October 26, the company rating was downgraded by Bank of America. The firm has “Overweight” rating given on Friday, September 23 by Piperjaffray. Below is a list of GlaxoSmithKline plc (ADR) (NYSE:GSK) latest ratings and price target changes.26/10/2017 Broker: Bank of America Rating: Hold Downgrade08/09/2017 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Underweight Downgrade05/07/2017 Broker: Citigroup Old Rating: Buy New Rating: Neutral Downgrade16/06/2017 Broker: J P Morgan Chase Co Rating: Neutral Maintain26/05/2017 Broker: Berenberg Old Rating: Hold New Rating: Buy Upgrade About 2.31 million shares traded. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 4.26% since November 7, 2016 and is uptrending. It has underperformed by 12.44% the S&P500.GlaxoSmithKline plc is a global healthcare company. The company has market cap of $86.69 billion. The Firm operates through three divisions: Pharmaceuticals, Vaccines and Consumer Healthcare. It has a 28.62 P/E ratio. The Firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus /infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.